Thursday, November 2, 2017
3:00 – 5:00 p.m.
Change the Face of the Opioid Landscape One Patient at a Time with Multimodal Treatment Approach
DePuy Synthes/Pacira Pharmaceuticals
A moderated discussion on the clinical significance of the Postsurgical Infiltration of Long Lasting Analgesia in TKA Results (PILLAR) trial, a phase 4 multicenter randomized controlled study (16 centers, 139 patients). The key learning objective is to educate on how a liposomal bupivacaine-based multimodal pain regimen of oral acetaminophen, celecoxib, and pregabalin compares to bupivacaine-based with respect to postsurgical pain and opioid reduction, as well as secondary endpoints including discharge readiness and hospital length of stay. In addition, attendees will learn the technique and importance of standardization to outcomes for multimodal pain management with liposomal bupivacaine. The symposium will be moderated by Mark I. Froimson, MD, MBA, and include a panel of 4-6 orthopaedic surgeons including PILLAR trial investigators.
Friday, November 3, 2017:
10:00 a.m. – 12:00 p.m.
Technology Advancements in Anterior Approach
Hear from Andrew J. Cooper, MD and Atul F. Kamath, MD on new innovations designed to aid in the Anterior Approach, including the ACTIS® Total Hip System, JointPoint™, and ME1000® Surgical Impactor. Attendees will learn more about how these technologies can help reduce the learning curve in the Anterior Approach and increase reproducibility in total hip arthroplasty.